DexCom, Inc. (NASDAQ:DXCM) Position Trimmed by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 11.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 26,130 shares of the medical device company’s stock after selling 3,425 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in DexCom were worth $2,032,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Private Trust Co. NA boosted its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares during the period. Optiver Holding B.V. bought a new stake in DexCom in the 4th quarter valued at about $33,000. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter worth about $38,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of DexCom stock opened at $85.67 on Friday. The stock has a market capitalization of $33.59 billion, a price-to-earnings ratio of 59.91, a P/E/G ratio of 2.30 and a beta of 1.43. The firm’s 50-day moving average price is $71.70 and its two-hundred day moving average price is $77.51. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.26.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the company earned $0.32 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis. On average, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. This represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,926 shares of company stock worth $4,734,384. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DXCM. Robert W. Baird cut their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They set an “outperform” rating and a $85.00 target price on the stock. Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Cfra Research upgraded shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $98.11.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.